NCT05824559View on ClinicalTrials.gov

ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

August 7, 2023

Primary Completion Date

July 9, 2024

Study Completion Date

July 23, 2024

Conditions
Colorectal Cancer
Interventions
DRUG

ME-344

ME-344 will be administered intravenously (IV)

DRUG

Bevacizumab

Bevacizumab will be administered intravenously (IV)

Trial Locations (7)

10029

Mt Sinai New York, New York

21218

Johns Hopkins, Baltimore

33140

Mount Sinai Miami, Miami Beach

37232

Vanderbilt -Ingram Cancer Center, Nashville

84108

University of Utah, Salt Lake City

90033

University of Southern California, Los Angeles

08901

Rutgers University, New Brunswick

Sponsors

Lead Sponsor

MEI Pharma, Inc.
All Listed Sponsors
lead

MEI Pharma, Inc.

INDUSTRY

NCT05824559 - ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter